Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Reading The Tea Leaves For Pharma Q1 Earnings

Diagnostics Companies’ Pre-Announcements Presage Pressures On Drug Revenues

Executive Summary

Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.

You may also be interested in...



Tumbling Medtech Investment Records Leave A Hill To Climb In 2022

Listing all-time high medtech IPO and M&A activity, Silicon Valley Bank’s 2021 health care investments and exits report made good reading after the market uncertainties induced by the pandemic a year earlier. But where does the sector go now after such a sterling year?

US Government Opposes Proposed Illumina/Grail Merger

Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.

Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D

Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel